Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 57Mesothelioma 35Unspecified Adult Solid Tumor, Protocol Specific 25Solid Tumor 9Advanced Solid Tumors 8Advanced Solid Tumor 7Solitary Fibrous Tumor, Pleural 6Carcinoma, Non-Small-Cell Lung 6Sarcoma 4Lung Neoplasms 4Solid Tumors 3Peritoneal Neoplasms 3Neoplasms 3Stomach Neoplasms 2Retinoblastoma 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Extensive Stage Small Cell Lung Cancer 2Colorectal Neoplasms 2Colonic Neoplasms 2Central Nervous System Neoplasms 2Breast Neoplasms 2Advanced Solid Tumour 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1

Interventions

amatuximab 1Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Severe combined immunodeficiency with sensitivity to ionizing radiation × Cisplatin × Other solid neoplasm × Clear all
NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡